ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Search Videos by Topic or Participant
Browse by Series:

Managing Bone Health in Prostate Cancer

Panelists: David Albala, MD, Crouse Hospital; E. David Crawford, MD, University of Colorado ; Raoul S. Concepcion, MD, Urology Associates, PC; Vahan Kassabi
Published: Thursday, Dec 19, 2013
For High-Definition, Click
Androgen deprivation therapy (ADT) is associated with significant bone mineral density loss. A variety of options should be utilized together in order to manage this side effect, states Stephen J. Freedland, MD, from the Duke University School of Medicine.

A few approaches to promote bone health, that urologists often forget to recommend, include exercise and vitamins. Exercise has been shown to preserve bone and bone density, specifically in men on ADT. Moreover, supplementation with calcium and 800 IU of vitamin D helps maintain bone health. These measures are still important, even when utilizing pharmaceuticals, such as denosumab (Xgeva).

In general, bone mineral loss begins the moment ADT is begun, making prophylactic measures more important. Moderator, Raoul S. Concepcion, MD, from Urology Associates, PC, suggests beginning denosumab at the same time as LHRH therapy. In generally, Concepcion believes, many urologists overlook bone health, representing a major education hurdle.

Slider Left
Slider Right
For High-Definition, Click
Androgen deprivation therapy (ADT) is associated with significant bone mineral density loss. A variety of options should be utilized together in order to manage this side effect, states Stephen J. Freedland, MD, from the Duke University School of Medicine.

A few approaches to promote bone health, that urologists often forget to recommend, include exercise and vitamins. Exercise has been shown to preserve bone and bone density, specifically in men on ADT. Moreover, supplementation with calcium and 800 IU of vitamin D helps maintain bone health. These measures are still important, even when utilizing pharmaceuticals, such as denosumab (Xgeva).

In general, bone mineral loss begins the moment ADT is begun, making prophylactic measures more important. Moderator, Raoul S. Concepcion, MD, from Urology Associates, PC, suggests beginning denosumab at the same time as LHRH therapy. In generally, Concepcion believes, many urologists overlook bone health, representing a major education hurdle.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x